The determination of citrate in blood and urine is clinically useful in certain situations. Measurements of serum citrate can be helpful in monitoring for citrate toxicity during transfusions of very large amounts of blood and blood products. I Citrate in urine inhibits crystal formation and measurements can be used to assess the risk of stone formation.?
Colorimetric and chromatographic methods have been used for citrate analysis but these are slow and not adaptable to automated analysis. A specific enzymatic method, involving bacterial citrate lyase (CL; Ee. 4.1.3.6) coupled with malate dehydrogenase (MDH) and L-lactate dehydrogenase (L-LD), has been used to determine citrate in foodstuffs, and the principle of this technique has been applied to citrate analysis in clinical samples. Citrate is first converted to oxaloacetate and acetate. In the presence of MDH and L-LD, oxaloacetate and its decarboxylation product pyruvate (the enzyme prepartion also contains oxaloacetate decarboxylase, OD) are then reduced to L-malate and t-t.actate by NADH. 
Materials and methods
The kits are supplied by BCL. For determination on the MIRA the reagents are reconstituted as follows: Bottle I which contains buffer, coupling enzymes, NADH and stabilisers is reconstituted with 26·4 mL distilled water; Bottle 2 which contains CL (the start reagent) is reconstituted with I· 5mL distilled water. The concentrations of the reagents in the final reaction mixture are identical with those obtained by the kit manual procedure.
The assay is standardised with an aqueous citrate standard of 1000 Jlmol/L.
The kit contains an aqueous standard with an assigned value. Low and medium level solutions are prepared from this solution by dilution to be used as quality controls. PROCEDURE The MIRA is programmed as shown in Table I . On the MIRA, the sample volume is reduced to 20 JlL (kit procedure 200 JlL). The sample, wash diluent (32 JlL) and reagent I (220 JlL) are dispensed into the disposable cuvette ring. This solution is incubated for 4 cycles (the MIRA operates on a fixed time analysis cycle of 25 s) at which point a blank reading is taken (AI)' The start reagent, CL (10 JlL), and wash diluent (20 JlL) are added on the fifth cycle. This solution is incubated for a further 4 cycles at which point the final absorbance is measured (A 2 ) . The instrument is programmed to read a separate wash diluent/reagent I cuvette as a reagent blank. The instrument's integral microprocessor calculates the citrate concentration by subtracting A, from A 2 and comparing the absorbance change with that of the standard.
Results
The standard curve on the MIRA was linear to 2250 Jlmol/L. The sensitivity of the assay was 30 Jlmol/L. The within-and between-batch precision was determined at three different levels for both serum and urine. The results are shown in Table 2 . The mean recovery of citrate added to serum samples (n = 20) was 98·5% (CV 2·1%) and to urine samples (n=20) 100·8% (CY 3,5%).
Aliquots of freshly separated serum and voided urine were stable for at least one week when stored both at room temperature and 4°C and for several months when stored at -20°C. The effect of pH on urine analysis was not investigated. 
General

Discussion.
We have described a simple, fast automated method for measuring serum and urine citrate with excel1ent precision and accuracy. The reconstitution volumes of the reagents were modified from those recommended in the kit insert for the manual procedure. The volume of Bottle I was modified to allow a single reagent addition (water is added as a second reagent in the manual procedure) and to take account of water added as a wash/diluent fol1owing addition of sample and start reagent. The volume of Bottle 2 was increased so that a larger and more accurate pipetting volume could be used. We found that although the working reagents were more dilute than recommended, their stability was not affected.
The manual method is performed at room temperature and a 5 min incubation is recommended before the first absorbance measurement is made to allow completion of sample and reagent side reactions. This is fol1owed by a further 5 min incubation after addition of CL before the final absorbance is measured. The reaction temperature on the MIRA is 37°C, so we found that the reaction times could each be reduced to 100 s with no deleterious effect on the results.
The expected range of citrate concentration in normal individuals is less than 150 jlmol/L, which is wel1 within the working range of the assay. Patients receiving blood transfusions, however, can have very high levels of serum citrate and samples may require dilution. Normal urine may contain up to 10 mrnol/L citrate and should be analysed both neat and in dilution. Dilutions of serum and urine with water were found to be linear.
No pretreatment of serum samples was required. Reports have suggested that the proteins should first be removed by deproteinisation or ultrafiltration but we, like others," found this to be unnecessary. Performing the assay on the MIRA reduces the costs considerably. The kit is designed for 30 manual determinations. Approximately 360 can be obtained from each kit on the MIRA. At the current list price of the kit this reduces the reagent costs to less than 10 pence per test.
